B+
Bull case
0%
Probability
Target price
$56.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
EXEL
ExelixisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
1%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+43.5
Score
AI commentary
Sentiment is constructive but not emphatic. Primary-source earnings materials were supportive, and delayed sell-side reaction was directionally positive via multiple target raises. Market reaction was mixed: EXEL closed at $44.42 on May 5, jumped to $48.70 on May 6 (+9.6%), then retraced to $46.21 on May 7 (-5.1%); on May 8 it traded around $47.73 intraday. That pattern fits a monitoring thesis where investors accept the earnings quality and pipeline cadence, but still want more proof before paying materially above consensus target levels. Social-context coverage was not provided, so confidence rests mainly on filings, the earnings release, and trusted market-source follow-up.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalystPost-earnings execution and capital return follow-throughMedium impact
Q1 total revenue rose to $610.8 million and net product revenue to $555.0 million, Exelixis maintained 2026 revenue guidance, and the board authorized an additional $750 million repurchase through 2027; several post-print target raises followed, including Morgan Stanley to $50, Stifel to $47, TD Cowen to $55, and H.C. Wainwright to $56 [#8-K-2026-05-05] [#10-Q-2026-05-05].
2026-12-03eventZanzalintinib mCRC FDA reviewHigh impact
Management said the first zanzalintinib NDA, for previously treated metastatic colorectal cancer in combination with atezolizumab, is under active U.S. review with a target action date of December 3, 2026 [#8-K-2026-05-05].
2026-12-31catalyst2026 zanzalintinib readout cadenceHigh impact
Exelixis guided to key 2026 pipeline milestones including STELLAR-303 and STELLAR-304 data, enrollment progress in STELLAR-311, and initiation of STELLAR-316, while also adding STELLAR-202 and a new STELLAR-002 expansion cohort [#8-K-2026-05-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology